Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/76
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrodaty, Henryen
dc.contributor.authorAmes, David J.en
dc.contributor.authorBoundy, K.en
dc.contributor.authorSnowden, John A.en
dc.contributor.authorStorey, E.en
dc.contributor.authorYates, Marken
dc.date.accessioned2012-11-05T22:55:20Zen
dc.date.available2012-11-05T22:55:20Zen
dc.date.issued2001en
dc.identifier.govdoc00062en
dc.identifier.issn0025-729Xen
dc.identifier.urihttp://hdl.handle.net/11054/76en
dc.description.abstractClinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients with mild to moderate Alzheimer's disease (AD). Before initiating cholinesterase inhibitor therapy, patients should be thoroughly assessed, and the diagnosis confirmed, preferably by a specialist. Compliance with cholinesterase inhibitor therapy should be monitored and the response (in global, cognitive, functional and behavioural domains) reassessed after 2-3 months of treatment. Vitamin E may be protective against AD, and therapy with 1000 IU twice daily may be considered. There is insufficient evidence to support the use of other antioxidant agents, anti-inflammatory agents, monoamine oxidase B inhibitors, folate/homocysteine or antihypertensive drugs in patients with AD, or hormone replacement therapy in affected women.en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2012-11-05T22:55:20Z (GMT) No. of bitstreams: 0en
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2012-11-05T22:55:05ZNo. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2012-11-05T22:55:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2001en
dc.publisherAustralasian Medical Publishing Co.en
dc.titlePharmacological treatment of cognitive deficits in Alzheimer's disease.en
dc.typeJournal Articleen
dc.type.specifiedArticleen
dc.bibliographicCitation.titleJournal of the Australian Medical Associationen
dc.bibliographicCitation.volume175en
dc.bibliographicCitation.issue6en
dc.bibliographicCitation.stpage324en
dc.bibliographicCitation.endpage329en
dc.publisher.placePyrmont, NSW.en
dc.subject.healththesaurusREVIEWen
dc.subject.healththesaurusALZHEIMER DISEASE - DRUG THERAPYen
dc.subject.healththesaurusCHOLINESTERASE INHIBITORS - THERAPEUTIC USEen
dc.subject.healththesaurusHUMANSen
dc.subject.healththesaurusPRACTICE GUIDELINES AS TOPICen
dc.subject.healththesaurusUNITED STATESen
dc.subject.healththesaurusUNITED STATES FOOD AND DRUG ADMINISTRATIONen
dc.subject.healththesaurusCHOLINESTERASE INHIBITORSen
dc.date.issuedbrowse2001-01-01en
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat  
00062.pdfCopyright 2001. Reproduced with permission.3.06 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.